USP forum goes gratis
This article was originally published in The Tan Sheet
Executive Summary
The Pharmacopeial Forum becomes a free online resource starting in January, the U.S. Pharmacopeia says Sept. 8, allowing "greater participation in the standards-setting process for drugs, excipients and dietary supplements." PF is the nonprofit group's journal for public comment, giving manufacturers, regulators and other stakeholders a chance to provide feedback on proposed standards before they become official in USP's National Formulary. The May-June issue of PF sought comments on standards for bacopa monnieri, garcinia gummi-gutta and other Indian botanicals used in supplements and traditional medicines (1"The Tan Sheet" May 10, 2010, In Brief)
You may also be interested in...
USP standardizes Indian botanicals
The U.S. and Indian pharmacopeias jointly propose standards for the identity, strength, quality and purity of four botanical articles in multiple forms used in U.S. dietary supplements and Indian traditional medicines. Monographs for the botanicals bacopa monnieri, garcinia gummi-gutta, garcinia indica and plectranthus barbatus are in the May-June issue of Pharmacopeial Forum, USP said May 5. The Rockville, Md.-based organization seeks comments on the standards before they are finalized. USP will publish official monograph standards for the botanicals ashwagandha root, andrograpahis aerial parts and boswellia serrata in February 2011, USP said
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.